THERMOGENESIS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.67 USD | -2.36% |
|
-3.46% | +11.48% |
| Apr. 16 | ThermoGenesis Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 16.86M | Sales 2025 * | 21.11M | Capitalization | 5.33M |
|---|---|---|---|---|---|
| Net income 2024 * | 2M | Net income 2025 * | 5M | EV / Sales 2024 * | 0.32 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.25 x |
| P/E ratio 2024 * |
8.38
x | P/E ratio 2025 * |
3.35
x | Employees | 25 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on ThermoGenesis Holdings, Inc.
More press releases
| 1 day | -2.36% | ||
| 1 week | -3.46% | ||
| Current month | -2.35% | ||
| 1 month | -23.86% | ||
| 3 months | -17.13% | ||
| 6 months | -34.95% | ||
| Current year | +11.48% |
1 week
0.67
0.74
1 month
0.580.91
Current year
0.361.25
1 year
0.362.20
3 years
0.36142.20
5 years
0.36638.10
10 years
0.3618 359.12
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Chun Xu
CEO | Chief Executive Officer | 53 | 16-03-09 |
Jeffery Cauble
DFI | Director of Finance/CFO | 51 | 09-12-31 |
Wendy Samford
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Medford
BRD | Director/Board Member | 69 | 17-02-23 |
Joseph Thomis
BRD | Director/Board Member | 78 | 17-01-09 |
Xiao Chun Xu
CEO | Chief Executive Officer | 53 | 16-03-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.67 | -2.36% | 25,624 |
| 24-05-09 | 0.6862 | -1.97% | 4,832 |
| 24-05-08 | 0.7 | +2.64% | 3,413 |
| 24-05-07 | 0.682 | 0.00% | 6,561 |
| 24-05-06 | 0.682 | -1.73% | 4,891 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotes
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Sector
Office Equipment
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.67
USD
Average target price
5
USD
Spread / Average Target
+646.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.48% | 5.33M | |
| +10.45% | 8.23B | |
| -3.84% | 4.66B | |
| -7.28% | 2.9B | |
| +5.67% | 2.14B | |
| -25.01% | 1.15B | |
| -1.50% | 912M | |
| -7.09% | 815M | |
| -22.40% | 764M | |
| -23.70% | 681M |
- Stock Market
- Equities
- THMO Stock
